The latest update is out from Mesoblast Limited ( (AU:MSB) ).
Mesoblast Limited, a biotechnology company, will be added to the S&P/ASX 200 Index, replacing Arcadium Lithium PLC, which is being acquired by Rio Tinto Limited. This change, effective March 6, 2025, signifies a shift in the index composition, potentially impacting investor perceptions and market dynamics as Mesoblast gains increased visibility and credibility within the financial community.
More about Mesoblast Limited
YTD Price Performance: 21.82%
Average Trading Volume: 296,508
Technical Sentiment Consensus Rating: Sell
Current Market Cap: $1.94B
For detailed information about MSB stock, go to TipRanks’ Stock Analysis page.